{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Antibody",
      "COVID-19",
      "Multivalent",
      "Pandemic",
      "SARS-CoV-2",
      "Vaccine",
      "Variant"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "35838949",
  "DateCompleted": {
    "Year": "2022",
    "Month": "07",
    "Day": "19"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "08",
    "Day": "17"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1007/978-1-0716-2395-4_2"
    ],
    "Journal": {
      "ISSN": "1940-6029",
      "JournalIssue": {
        "Volume": "2511",
        "PubDate": {
          "Year": "2022"
        }
      },
      "Title": "Methods in molecular biology (Clifton, N.J.)",
      "ISOAbbreviation": "Methods Mol Biol"
    },
    "ArticleTitle": "Multivalent Vaccine Strategies in Battling the Emergence of COVID-19 Variants.",
    "Pagination": {
      "StartPage": "21",
      "EndPage": "36",
      "MedlinePgn": "21-36"
    },
    "Abstract": {
      "AbstractText": [
        "The emergence of new SARS-CoV-2 variants has led to increased transmission and more severe cases of COVID-19, with some having the ability to escape the existing vaccines. This review discusses the importance of developing new vaccine strategies to keep pace with these variants to more effectively manage the pandemic. Many of the new vaccine approaches include multivalent display of the most highly mutated regions in the SARS-CoV-2 spike protein such that they resemble a virus particle and can stimulate an effective neutralization response. It is hoped that such approaches help to manage the existing pandemic and provide a robust infrastructure toward fast tracking responses across the world in case of future pandemics."
      ],
      "CopyrightInformation": "\u00a9 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil. paulcguest@yahoo.com."
          }
        ],
        "LastName": "Guest",
        "ForeName": "Paul C",
        "Initials": "PC"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Methods Mol Biol",
    "NlmUniqueID": "9214969",
    "ISSNLinking": "1064-3745"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Spike Glycoprotein, Coronavirus"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Vaccines, Combined"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "spike protein, SARS-CoV-2"
    }
  ],
  "SupplMeshList": [
    "SARS-CoV-2 variants"
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "prevention & control"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Spike Glycoprotein, Coronavirus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vaccines, Combined"
    }
  ]
}